This study looks at patients with acute myeloid leukemia (AML) who have had a stem cell transplant, which is a procedure to replace damaged blood-forming cells. Doctors are trying to see if a test called measurable residual disease (MRD), which checks for tiny amounts of cancer, can help predict if the cancer might come back and how long patients might live. The study will last about 7 years, with people participating for about 3 years. During this time, up to 1,000 people will be asked to give blood samples at specific times after their transplant. They might also need to give bone marrow samples, which are taken from inside the bone.

• The study involves blood samples at 10 different times over 18 months and possibly more if cancer returns.
• Participants must be at least 18 years old, in complete remission from AML, and have not had a previous stem cell transplant.
• Participation is voluntary, and participants must agree to follow all study procedures for about 3 years.